Published in J Osteoporos on October 31, 2010
Thiazolidinediones on PPARγ: The Roles in Bone Remodeling. PPAR Res (2011) 0.85
Bone and the perimenopause. Obstet Gynecol Clin North Am (2011) 0.84
Serum free estradiol and estrogen receptor-α mediated activity are related to decreased incident hip fractures in older women. Bone (2012) 0.79
Progesterone for Symptomatic Perimenopause Treatment - Progesterone politics, physiology and potential for perimenopause. Facts Views Vis Obgyn (2011) 0.78
Ovulation Prevalence in Women with Spontaneous Normal-Length Menstrual Cycles - A Population-Based Cohort from HUNT3, Norway. PLoS One (2015) 0.76
Low-dose combined oral contraceptive use is associated with lower bone mineral content variation in adolescents over a 1-year period. BMC Endocr Disord (2015) 0.75
Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial. J Korean Med Sci (2017) 0.75
Genome-Wide Transcriptional Excavation of Dipsacus asperoides Unmasked both Cryptic Asperosaponin Biosynthetic Genes and SSR Markers. Front Plant Sci (2016) 0.75
Relationships between vertebral fractures, sex hormones and vitamin D in Moroccan postmenopausal women: a cross sectional study. BMC Womens Health (2015) 0.75
HOW CAN WE PROTECT PEAK BONE MASS AND FUTURE BONE HEALTH FOR ADOLESCENT WOMEN? - BY SUPPORTING OVULATION AND AVOIDING COMBINED HORMONAL CONTRACEPTION USE. Rev Paul Pediatr (2017) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 18.24
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril (2001) 5.36
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Changes in proinflammatory cytokine activity after menopause. Endocr Rev (2002) 3.24
Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med (1977) 2.59
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Spinal bone loss and ovulatory disturbances. N Engl J Med (1990) 2.31
Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. Clin Endocrinol (Oxf) (1996) 2.05
Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab (2006) 2.01
Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev (1998) 1.86
Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J (1973) 1.79
Calcium accretion in girls and boys during puberty: a longitudinal analysis. J Bone Miner Res (2000) 1.76
Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest (1996) 1.59
Urinary ovarian and gonadotropin hormone levels in premenopausal women with low bone mass. J Bone Miner Res (1998) 1.57
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat (2007) 1.55
Bone health is not affected by luteal phase abnormalities and decreased ovarian progesterone production in female runners. J Clin Endocrinol Metab (1997) 1.54
Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab (1996) 1.53
A prospective study of bone loss in menopausal Australian-born women. Osteoporos Int (1998) 1.50
Bone mass and subtle abnormalities in ovulatory function in healthy women. J Clin Endocrinol Metab (1996) 1.49
The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol (2005) 1.47
Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. J Clin Endocrinol Metab (2007) 1.44
Progesterone as a bone-trophic hormone. Endocr Rev (1990) 1.43
A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy. Br J Obstet Gynaecol (1997) 1.42
Menopause and hypothalamic-pituitary sensitivity to estrogen. JAMA (2004) 1.37
Hormonal profile of the cycle in 68 normally menstruating women. Acta Endocrinol (Copenh) (1980) 1.33
Quantum concept of bone remodeling and turnover: implications for the pathogenesis of osteoporosis. Calcif Tissue Int (1979) 1.32
Relationship of bone turnover to bone density and fractures. J Bone Miner Res (1997) 1.26
Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med (1991) 1.24
A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab (1992) 1.24
Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA (2002) 1.22
Bone mineral density and its change in pre-and perimenopausal white women: the Michigan Bone Health Study. J Bone Miner Res (1998) 1.22
Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int (2003) 1.19
Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. J Clin Endocrinol Metab (2005) 1.17
Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab (1984) 1.14
Serum inhibin A and inhibin B in healthy prepubertal, pubertal, and adolescent girls and adult women: relation to age, stage of puberty, menstrual cycle, follicle-stimulating hormone, luteinizing hormone, and estradiol levels. J Clin Endocrinol Metab (2000) 1.12
The corpus luteum: determinants of progesterone secretion in the normal menstrual cycle. Obstet Gynecol (1988) 1.11
Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause (2009) 1.10
Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study. Clin Chim Acta (2005) 1.10
Secondary amenorrhoea: prevalence and medical contact--a cross-sectional study from a Danish county. Br J Obstet Gynaecol (1992) 1.08
High bone turnover is associated with low bone mass in both pre- and postmenopausal women. Bone (1996) 1.06
Length and variation in the menstrual cycle--a cross-sectional study from a Danish county. Br J Obstet Gynaecol (1992) 1.05
Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab (1995) 1.04
Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med (1994) 1.02
Is progesterone a candidate neuroprotective factor for treatment following ischemic stroke? Neuroscientist (2009) 1.00
The mature osteoblast phenotype is characterized by extensive plasticity. Exp Cell Res (1997) 0.99
Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol (1999) 0.99
A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int (2001) 0.98
Serum steroids and pituitary hormones in female puberty: a partly longitudinal study. Clin Endocrinol (Oxf) (1980) 0.98
Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA (1980) 0.97
Interrelationships between ovarian and pituitary hormones in ovulatory menstrual cycles across reproductive age. J Clin Endocrinol Metab (2008) 0.96
Determination of luteal phase length by quantitative basal temperature methods: validation against the midcycle LH peak. Clin Invest Med (1990) 0.96
A prospective investigation of the relations among cognitive dietary restraint, subclinical ovulatory disturbances, physical activity, and bone mass in healthy young women. Am J Clin Nutr (2007) 0.93
Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology (2008) 0.92
Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J Clin Endocrinol Metab (1990) 0.91
Influence of pattern of menopausal transition on the amount of trabecular bone loss. Results from a 6-year prospective longitudinal study. Maturitas (2006) 0.90
Detecting evidence of luteal activity by least-squares quantitative basal temperature analysis against urinary progesterone metabolites and the effect of wake-time variability. Eur J Obstet Gynecol Reprod Biol (2009) 0.90
Change in bone mass immediately before menopause. J Bone Miner Res (1992) 0.90
Estrogen receptor alpha regulates area-adjusted bone mineral content in late pubertal girls. J Clin Endocrinol Metab (2006) 0.90
A prospective exploration of cognitive dietary restraint, subclinical ovulatory disturbances, cortisol, and change in bone density over two years in healthy young women. J Clin Endocrinol Metab (2010) 0.90
Changes in bone resorption during the menstrual cycle. J Bone Miner Res (1999) 0.90
Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Am J Obstet Gynecol (1997) 0.89
Stimulatory effects of estrogen and progesterone on proliferation and differentiation of normal human osteoblast-like cells in vitro. Biochem Biophys Res Commun (1992) 0.88
Eating attitudes and habitual calcium intake in peripubertal girls are associated with initial bone mineral content and its change over 2 years. J Bone Miner Res (2001) 0.86
Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res (1997) 0.85
Relationship of the menstrual cycle pattern in 14-17 year old old adolescents with gynaecological age, body mass index and historical parameters. Hum Reprod (1998) 0.85
Lean body mass, not estrogen or progesterone, predicts peak bone mineral density in premenopausal women. J Nutr (2008) 0.84
Ovulatory premenopausal women lose cancellous spinal bone: a five year prospective study. Bone (1996) 0.84
Vasomotor symptoms in infertile premenopausal women: a hitherto unappreciated risk for low bone mineral density. Fertil Steril (2008) 0.83
Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents. Hum Reprod (1999) 0.83
Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women. J Clin Endocrinol Metab (2000) 0.83
Daily measurements of salivary progesterone reveal a high rate of anovulation in healthy students. Scand J Clin Lab Invest (1989) 0.83
Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. Clin Sci (Lond) (2007) 0.83
Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin Endocrinol (Oxf) (1994) 0.82
Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J Clin Endocrinol Metab (1998) 0.82
Bone metabolism during the perimenopausal transition: a prospective study. Maturitas (2002) 0.81
Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol (1991) 0.81
Changes of biochemical bone markers during the menopausal transition. Clin Chem Lab Med (2002) 0.81
FSH and bone--important physiology or not? Trends Mol Med (2006) 0.81
Vegetarian vs nonvegetarian diets, dietary restraint, and subclinical ovulatory disturbances: prospective 6-mo study. Am J Clin Nutr (1994) 0.80
Effect of long-term administration of progestogen on post-menopausal bone loss: result of a two-year, controlled randomized study. Clin Endocrinol (Oxf) (1993) 0.79
Progesterone and promegestone stimulate human bone cell proliferation and insulin-like growth factor-2 production. Acta Endocrinol (Copenh) (1992) 0.79
Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. J Endocrinol Invest (2002) 0.79
The ageing female reproductive axis II: ovulatory changes with perimenopause. Novartis Found Symp (2002) 0.79
Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Arch Sex Behav (1989) 0.78
A potential role of endogenous progesterone in modulation of GH, prolactin and thyrotrophin secretion during normal menstrual cycle. Clin Endocrinol (Oxf) (2009) 0.78
Menstrual cycle lengths and bone mineral density: a cross-sectional, population-based study in rural Chinese women ages 30-49 years. Osteoporos Int (2006) 0.78
Is there an association between vasomotor symptoms and both low bone density and cardiovascular risk? Menopause (2009) 0.75
Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med (2007) 4.68
Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol (2002) 2.75
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24
A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res (2014) 1.56
Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women. Menopause (2012) 1.44
Community-based exercise program reduces risk factors for falls in 65- to 75-year-old women with osteoporosis: randomized controlled trial. CMAJ (2002) 1.38
Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res (2010) 1.37
Age at menarche in the Canadian population: secular trends and relationship to adulthood BMI. J Adolesc Health (2008) 1.29
Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res (2007) 1.28
The association between body mass index and health-related quality of life: data from CaMos, a stratified population study. Qual Life Res (2007) 1.26
Association between change in BMD and fragility fracture in women and men. J Bone Miner Res (2009) 1.19
Temporal trends and determinants of longitudinal change in 25-hydroxyvitamin D and parathyroid hormone levels. J Bone Miner Res (2012) 1.18
Meta-analysis of genome-wide studies identifies WNT16 and ESR1 SNPs associated with bone mineral density in premenopausal women. J Bone Miner Res (2013) 1.16
Evaluation of methods and costs associated with recruiting healthy women volunteers to a study of ovulation. J Womens Health (Larchmt) (2010) 1.09
Dietary patterns in Canadian men and women ages 25 and older: relationship to demographics, body mass index, and bone mineral density. BMC Musculoskelet Disord (2010) 1.08
Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2004) 1.06
Dietary patterns and incident low-trauma fractures in postmenopausal women and men aged ≥ 50 y: a population-based cohort study. Am J Clin Nutr (2010) 1.06
Retracted Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study. Am J Kidney Dis (2009) 1.05
Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res (2009) 1.00
Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos). J Clin Endocrinol Metab (2013) 0.99
Spine-hip T-score difference predicts major osteoporotic fracture risk independent of FRAX(®): a population-based report from CAMOS. J Clin Densitom (2011) 0.97
Negative spinal bone mineral density changes and subclinical ovulatory disturbances--prospective data in healthy premenopausal women with regular menstrual cycles. Epidemiol Rev (2013) 0.95
Changes in body mass index in Canadians over a five-year period: results of a prospective, population-based study. BMC Public Health (2007) 0.92
Independent external validation of nomograms for predicting risk of low-trauma fracture and hip fracture. CMAJ (2010) 0.92
Health-related quality of life in Canadian adolescents and young adults: normative data using the SF-36. Can J Public Health (2010) 0.91
What is the number of older Canadians needed to screen by measurement of bone density to detect an undiagnosed case of osteoporosis? a population-based study from CaMos. J Clin Densitom (2006) 0.90
Detecting evidence of luteal activity by least-squares quantitative basal temperature analysis against urinary progesterone metabolites and the effect of wake-time variability. Eur J Obstet Gynecol Reprod Biol (2009) 0.90
A prospective exploration of cognitive dietary restraint, subclinical ovulatory disturbances, cortisol, and change in bone density over two years in healthy young women. J Clin Endocrinol Metab (2010) 0.90
Ovulation disturbances and mood across the menstrual cycles of healthy women. J Psychosom Obstet Gynaecol (2009) 0.86
Fracture risk prediction: importance of age, BMD and spine fracture status. Bonekey Rep (2013) 0.81
Dual-Energy X-Ray Absorptiometry Technical issues: the 2007 ISCD Official Positions. J Clin Densitom (2008) 0.81
Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMos). Arch Osteoporos (2014) 0.78
Prospectively measured 10-year changes in health-related quality of life and comparison with cross-sectional estimates in a population-based cohort of adult women and men. Qual Life Res (2014) 0.78
Bone changes and fracture related to menstrual cycles and ovulation. Crit Rev Eukaryot Gene Expr (2010) 0.78
Parity and subfertility effects of continuous oral contraceptive on fertility are important. Fertil Steril (2009) 0.77
Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy. Pharmacotherapy (2010) 0.77
Hot flushes and night sweats differ in associations with cardiovascular markers in healthy early postmenopausal women. Menopause (2012) 0.77
Osteoporosis: What a clinician expects to learn from a patient's bone density examination. Radiology (2003) 0.77
Changes in pulmonary transfer factor with menstrual cycle phase. Respir Physiol Neurobiol (2005) 0.76
Evidence about extending the duration of oral contraceptive use to suppress menstruation. Womens Health Issues (2004) 0.76
Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause (2008) 0.75
Night sweats are commonly vasomotor symptoms. Am Fam Physician (2004) 0.75
Effectiveness of ERr 731 in the management of symptomatic perimenopause: clinical significance. Menopause (2007) 0.75
Fluid Retention over the Menstrual Cycle: 1-Year Data from the Prospective Ovulation Cohort. Obstet Gynecol Int (2011) 0.75
Unsuccessful attempt to demonstrate progesterone's bone formation actions. Am J Obstet Gynecol (2006) 0.75